Systemic Alpha-2 Adrenergic Agonist Use Linked to Reduced Glaucoma Risk

Patients on therapy for hypertension also benefit from a reduced risk of glaucoma. Photo: Actavis. Click image to enlarge. A recent study found that, among adults with hypertension, systemic alpha-2 adrenergic agonists (α₂-agonists) were associated with a significantly lower risk of ocular hypertension (OHT) and primary open-angle glaucoma (POAG) development than systemic beta-blockers. Their paper on the study was published in BMJ Open Ophthalmology.Researchers conducted a study using electronic health records from the TriNetX database. The analysis included adults aged 40 years and older with hypertension who had chronic exposure to either systemic α₂-agonists (clonidine, guanfacine, dexmedetomidine or methyldopa) or systemic beta-blockers. To ensure sustained medication use, participants were required to have received “at least four prescriptions of the assessed medication” and “a minimum of three eye examinations within five years following initiation of the exposure medication,” as described by the researchers in the study. Patients with preexisting OHT or POAG were excluded.A total of 4,152 patients were included in the study, divided into groups based on whether they used α₂-agonists or beta-blockers. Members of both groups were matched to members in the other, with an additional remaining unmatched cohort. The patients’ mean age was 59.7; 38.7% were male in the α₂-agonists group and 39.5% were male in the beta-blocker group. The α₂-agonist group also consisted of 62.4% white patients, 25.7% Black patients and 2.4% Asian patients; among the beta-blocker group, 65.3% were white, 20.6% were Black and 4.4% were Asian. Common comorbidities included myopia (18.4% in α₂-agonist users, 10.8% in beta-blocker users), obesity (46%; 43.4%) and diabetes (41.1%; 30.1%).In the matched analysis, OHT rates were significantly lower among α₂-agonist users at five years. POAG rates were also lower at three years and five years. Results are shown below:Adjusted Hazard Ratio(vs. Beta-Blockers)OHTPOAG1 year0.5820.3593 years0.5590.3335 years0.5340.334 Similarly, a further analysis of the unmatched patients showed that α₂-agonists were associated with a lower hazard of OHT at one year, three years and five years than beta-blockers.The authors proposed in the paper that “these findings indicate an association between systemic α₂-agonist use and lower glaucoma hazard compared with β-blockers, suggesting possible differences in their ocular or neurovascular effects.” However, they also noted a possible limitation in that the study relied on an “observational design, potential residual confounding and reliance on diagnostic coding.” They concluded that further “prospective mechanistic studies and randomized clinical trials” are needed to determine whether α₂-agonists can directly influence glaucoma development or progression.Click here for the journal source. Abboud I, Khudari AZ, Abdelaal A, et al. Systemic α2-agonist use and lower hazard of glaucoma compared with β-blockers: a cohort study. BMJ Open Ophthalmol. April 26, 2026. [Epub ahead of print].  This article was developed by the editorial staff in conjunction with experts in the field. In the process, AI may have been among the editorial tools used to meet the goals of human editors, who approved all content.